Amorphical's Transformative Nano-Amorphous Mineral Solutions for Bioavailability and Anti-Inflammatory Fundamental Challenges
Amorphical Ltd., an Israeli biotechnology firm, is pioneering pharmaceuticals for metabolic, bone, and inflammatory diseases, utilizing innovative nanoparticulate amorphous carbonate mineral technology. Its research and development center on Amorphous Calcium Carbonate (ACC), which exhibits unique biomedical capabilities due to its combined chemical and physical characteristics (unlike its crystalline phases). Amorphical has realized and demonstrated that ACC is a game-changing, safe biomedical substance that efficiently responds to the common denominator—local acidosis—of harmful and life-threatening groups of diseases associated with inflammatory activities. The unheard-of utilization of crafted and safe “minerals” as a therapeutic drug for severe diseases is a standalone game-changer, releasing naturally active components essential to normal body functions.
With over 180 worldwide patents, Amorphical conducts its R&D and operations with over 200 team members through collaboration with more than 10 medical research centers in Israel and Taiwan. The company's ISO-certified food-grade manufacturing facilities in Israel are being upgraded to Pharma-GMP standards, expected by the end of 2025.
In contrast to crystalline forms of calcium carbonate, Amorphical’s transformative lead product—ACC has demonstrated enhanced bioavailability and solubility, enabling effective calcium delivery and buffering acidotic environments. Amorphical's clinical portfolio leverages this unique combination of characteristics to validate novel treatments for diseases and conditions benefiting from (1) calcium absorption boost, and (2) targeted acidotic/inflamed environments.
Strategically, Amorphical performs a Phase-2 clinical trial under the FDA monitoring (via an approved IND) for treating hypoparathyroidism—an orphan disease, to regulatory approve its active substance at the fastest regulatory track. Simultaneously, the company is advancing with clinical studies of several other indications. The company is pursuing treatments for diseases that currently have unsatisfactory, very expensive, or harmful therapeutic solutions, such as osteoporotic fractures, Stage 4 pancreatic cancer, and Crohn's disease. The tested treatments are performed with the same active substance utilizing various modes of administration (including unconventional ones) to reach the targeted damaged organs. This approach will streamline the regulatory processes and expand the market reach. Amorphical’s ACC has shown promising results in early-phase clinical trials for hypoparathyroidism, osteoporosis, COVID-19, and inflammatory diseases, as well as in compassionate treatments for various Stage-4 cancers. Meanwhile, Amorphical’s Taiwanese partner explores the ACC's osteopenia benefits and synergistic effects with other bone health treatments.
https://www.amorphical.com for more information and access to Amorphical’s scientific publications